Medicine News

• Biogen Idec And Knopp Neurosciences Announce License Agreement For Late-Stage ALS Drug C ...
  Sat, 21 August 2010
  Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other i ...
• GlaxoSmithKline And Human Genome Sciences Announce FDA Priority Review Designation For B ...
  Sat, 21 August 2010
  GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to Benlysta (belimumab) as a potential treatment for systemic lupus erythematosus (SLE)...
• Lupus Drug Benlysta (belimumab) Priority Review Granted By FDA
  Fri, 20 August 2010
  Benlysta (belimumab), a potential treatment for systemic lupus erythematosus has been granted a priority review designation by the FDA (Food and Drug Administration, USA), which is granted to medications, that if approved, offer significant treatment advances or provide treatment when no proper therapy exists...
• Substantial Costs Associated With Scientific Misconduct Should Prioritize Prevention Efforts
  Fri, 20 August 2010
  The estimated costs associated with a single investigation of scientific misconduct can be as high as US 525,000, and the costs of investigating the allegations of scientific misconduct annually reported in the United States to the Office of Research Integrity (ORI), could exceed US110 million, according to a paper from Arth ...
• Optimizing Early Phase Oncology Studies To Accelerate Proof Of Concept, 29-30 September ...
  Fri, 20 August 2010
  When running early clinical trials for experimental new drugs across a range of therapeutic areas, demonstrating proof of concept is a critical milestone of the development process. It is at this stage where exploratory studies become confirmatory studies and there is a basis for studying the efficacy in a larger population...
• Quality Issue Roundup: J & J Revamping Controls; The Odds For Orthopedic Surgery; Automa ...
  Fri, 20 August 2010
  The New York Times: Johnson & Johnson has said it will revamp its quality controls, creating a single framework for its drug, medical device and consumer health care divisions...
• Multi-centre Phase II Trial Reports Safety And Clinical Benefits Of Radioactive Microsph ...
  Fri, 20 August 2010
  Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II tr ...
• US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access To Cutt ...
  Fri, 20 August 2010
  US Oncology, Inc., the nation's leading integrated oncology company, announced that in less than two decades it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration (FDA)...
• SRI International To Advance Clinical Development Of TAS-108, A Late-Stage Breast Cancer ...
  Fri, 20 August 2010
  SRI International, an independent nonprofit research and development organization, announced that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company...
• PAREXEL Introduces Temperature Recording Solution For Study Drug Transportation, Bringin ...
  Fri, 20 August 2010
  PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services...